Message from the Director

One of the original units of the National Cancer Center (NCC), the National Cancer Center Hospital (NCCH) has lead the nation’s cancer care and research since its establishment in 1962, under the mission of “providing best medicine to all citizens, working with the public”.Today, with one in two citizens developing cancer, it remains a challenging illness to overcome. We shall continue to meet the high demand for first-rate treatments, for cancers of all organs.

Designated as an incorporated administrative agency in 2010, we continue to provide high-quality services as the core of the nation’s cancer medicine and develop new, more effective and safer treatments. Without being complacent, we strive to improve patient satisfaction in outpatient consultations, services and support, whilst developing minimally invasive treatments such as endoscopy and interventional radiology at early stages, as well as high precision radiation therapy. To bolster these efforts, the Robotic Surgery Center was established.

Clinical research is another important undertaking. In collaboration with the research institute and other units within NCC, we conduct whole genome sequencing and translational research while training researchers and strengthening informatics. Developing treatments for rare and refractory cancers, meeting unmet needs is another crucial responsibility. Designated as a global clinical trial core center in 2015 and subsequently as a cancer genomic medicine core hospital in 2018, we lead in both the quality and quantity of clinical trials and cancer genomic medicine research. These activities are safely conducted in-house, and we also support external institutions in their efforts, towards developing next generation cancer medicine. As a cancer genomic medicine core hospital, we provide precision medicine and foster stronger collaborative relationship with other medical institutions. To this end, we recognize the urgent need for further digitalization, to leverage the full potential of the latest technology.

At the Supportive Care Development Center established in 2016, we focus on alleviating the pain and anxiety experienced by patients and their families, as well as addressing the challenges and inconveniences they face in their daily lives, including work-related issues. Ongoing research on supportive and palliative care is conducted through the J-SUPPORT (Japan Supportive, Palliative and Psychosocial Oncology Group) project, to accumulate scientific evidence. For such activities to bear fruit, patient engagement is essential, and we deeply appreciate the kind cooperation we receive from all involved.

We are committed to delivering the highest-quality cancer medicine to as many patients as possible, prioritizing clinical safety, collaboration with patients and communities, and high-performance work systems. We eagerly anticipate and welcome your candid feedback and opinions, as we deeply value the support from everybody involved in this endeavor.

Dr Yasuyuki Seto, MD PhD
Director
National Cancer Center Hospital